|Videos|April 21, 2022
The Role of Biomarkers in Immunotherapy Selection for mUC
Experts discuss the role of biomarkers in treatment selection for patients with metastatic UC.
Advertisement
Episodes in this series
Advertisement
Related to this article
The robotic endoscopy system obtained detrusor muscle in 94% of resected bladder lesions among the first 20 patients treated in the VIABLE study.
Real-world data showed a 68% 12-month high-grade recurrence-free survival rate with hyperthermic mitomycin C in patients with BCG-unresponsive NMIBC.
Israel approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS, expanding access beyond the US, UK, EU, Saudi Arabia, and UAE.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
European Commission Expands Melflufen Label to Third-Line Multiple Myeloma
5